안티에이징 의약품 시장 : 세계 예측(-2040년) : 분자 유형별, 노화 유형별, 지역별, 의약품 판매 예측

Anti-Aging Drugs Market: Overview

As per Roots Analysis, the anti-aging drugs market is estimated to grow from USD 79 million in the current year to USD 2,807 million by 2040, representing a higher CAGR of 27% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Molecule

• Biologics
• Small Molecules

Type of Aging

• Cellular Aging
• Immune Aging
• Metabolic Aging
• Others

Geographical Regions

• North America
• Europe
• Asia Pacific
• Rest of the World

Anti-Aging Therapeutics Market: Growth and Trends

Researchers and innovators worldwide are focusing their efforts on the development of therapeutics that can extend life expectancy of an individual by targeting the pathophysiology of aging. Numerous start-ups and academic / research institutes globally are exploring a variety of anti-aging therapies at various stages of development. It is worth mentioning that anti-aging drug providing companies are using various methods, such as advancements in rigorous clinical trial services to expedite market approval procedure and incorporation of artificial intelligence to develop better anti-aging drugs. Additionally, technological advancements like organ-on-chip (promising alternative to conventional testing procedures) in the anti-aging domain has resulted in the development of targeted and effective longevity drugs. With the growing geriatric population, the ongoing R&D initiatives and the increasing funding investments, the anti-aging therapeutics market is expected to experience significant growth in the foreseen future.

With the growing geriatric population, the ongoing R&D initiatives and the increasing funding investments, the anti-aging therapeutics market is expected to experience significant growth in the foreseen future.

Anti-Aging Therapeutics Market: Key Insights

The report delves into the current state of the anti-aging therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, more than 65 anti-aging therapeutics are being developed worldwide; majority of the developers are small firms based in North America.
• These therapeutics, ranging from a variety of biologics and small molecules, are currently being investigated across different phases of development.

• More than 55% of partnership agreements were inked in the past two years.
• ~USD 4 billion has been invested by both private and public investors, since 2018
• Over 660 patents related to anti-aging therapeutics have recently been filed / granted, indicating the growing intellectual capital in this domain.
• 230+ articles related to anti-aging therapeutics have been published over the last four years.

• The market is expected to grow at an annualized rate of over 15%; the overall opportunity is anticipated to be well distributed across different types of molecules, types of aging and key geographical regions.
• Europe and Asia Pacific are anticipated to capture more than 75% of the market share, by 2040.

Anti-Aging Therapeutics Market: Key Segments

Small Molecules Holds the Largest Market Share of the Overall Anti-Aging Therapeutics Market

In terms of type of molecule, the anti-aging therapeutics market is segmented across biologics and small molecules. Our estimates suggest that small molecules are likely to capture most of the market share in the current year. Further, this segment is likely to grow at a relatively higher CAGR during the forecast period.

Asia-Pacific is Expected to Propel in the Anti-aging Drugs Market in the Coming Years

In terms of geographical regions, the anti-aging therapeutics market is segmented across North America, Europe, Asia-Pacific and rest of the world. Currently, North America captures the majority of the market, and this trend is likely to remain the same in the future. Further, the market in Asia-Pacific is likely to grow at a relatively higher CAGR during the forecast period.

Example Players in the Anti-aging Therapeutics Market

• AgelessRx
• ANOVA Institute of Regenerative Medicine
• Betterhumans
• BioAge Labs
• bioXcellerator
• Cambrian Biopharma
• Gero.ai, Mayo Clinic
• Rejuvenate Bio
• UT Health San Antonio

Anti-Aging Therapeutics Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global anti-aging therapeutics market, in terms of the key market segments, namely [A] type of molecule [B] type of aging, [C] geographical regions and [C] sales forecast of drugs.
• Market Landscape: An in-depth assessment of the companies involved in anti-aging therapeutics market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] phase of development, [E] type of aging, [F] type of molecule, [G] mechanism of action, [H] type of developer.
• Company Competitiveness Analysis: A comprehensive competitive analysis of anti-aging therapeutics market, examining factors, such as [A] developer strength and [B] portfolio strength and [C] portfolio diversity.
• Company Profiles: Detailed profiles of key developers engaged in the anti-aging therapeutics market, focused on [A] overview of the company, [B] financial information (if available), [C] drug portfolio, and [D] recent developments and an informed future outlook.
• Patent Analysis: An insightful analysis of the various patents filed / granted in anti-aging therapeutics market, based on various parameters, such as [A] type of patent [B] patent publication year [C] geography, [D] CPC Symbols, [E] type of applicant, [F] emerging focus area, [G] patent age, [H] patent benchmarking [I] patent characteristics [J] patent valuation.
• Publication Analysis: An insightful analysis of the overall publications reported in this domain, based on various parameters, such as [A] year of publication [B] type of publication and [C] geography.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Overview of Aging
• 3.2. Types of Aging
• 3.3. Causes of Aging
• 3.4 Mechanism of Action of Anti-aging drugs market
• 3.5 Age-related Diseases
• 3.6 Key Facts Associated with Aging
• 3.7 Future Perspectives of Anti-aging drugs

4. MARKET LANDSCAPE

• 4.1. Anti-aging Drugs: Overall Market Landscape
  • 4.1.1. Analysis by Phase of Development
  • 4.1.2. Analysis by Type of Aging
  • 4.1.3. Analysis by Phase of Development and Type of Aging
  • 4.1.4. Analysis by Type of Molecule
  • 4.1.5. Analysis by Mechanism of Action
  • 4.1.6. Analysis by Type of Developers
• 4.2. Anti-aging Drugs: Developer Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size and Location of Headquarters
  • 4.2.3. Leading Developers by Number of Therapeutics
  • 4.2.4. Regional Landscape of Developers

5. COMPANY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Assumptions and Key Parameters
• 5.3. Methodology
• 5.4. Anti-aging Drugs: Company Competitiveness Analysis
  • 5.4.1. Small Companies
  • 5.4.2. Mid-sized and Large Companies

6. PARTNERSHIPS AND COLLABORATIONS

• 6.1. Chapter Overview
• 6.2. Anti-aging Drugs: Partnerships and Collaborations
  • 6.2.1 Analysis by Year of Partnership
  • 6.2.2. Analysis by Type of Partnership
  • 6.2.3. Analysis by Year and Type of Partnership
  • 6.2.4. Leading Players: Analysis by Number of Partnerships
  • 6.2.5. Analysis by Type of Partner
  • 6.2.6. Analysis by Type of Agreement
  • 6.2.7. Analysis by Region
    • 6.2.7.1. Intercontinental and Intracontinental Deals
    • 6.2.7.2. International and Local Deals

7. FUNDING AND INVESTMENTS

• 7.1. Chapter Overview
• 7.2. Anti-aging Drugs: Funding and Investments
  • 7.2.1. Analysis of Instances by Year
  • 7.2.2. Analysis of Amount Invested by Year
  • 7.2.3 Analysis of Instances by Type of Funding
  • 7.2.4. Analysis of Amount Invested by Type of Funding
  • 7.2.5. Analysis by Type of Investor
  • 7.2.6. Analysis by Focus Area
  • 7.2.7. Analysis of Amount Invested by Region
  • 7.2.8. Analysis of Amount Invested by Country
  • 7.2.9. Most Active Investors: Analysis by Number of Instances
  • 7.2.10. Most Active Players: Analysis by Number of Instances
  • 7.2.11. Most Active Players: Analysis by Amount Invested

8. PATENT ANALYSIS

• 8.1. Chapter Overview
• 8.2. Scope and Methodology
• 8.3. Anti-aging Drugs: Patent Analysis
  • 8.3.1. Analysis by Type of Patent
  • 8.3.2. Analysis by Patent Publication Year
  • 8.3.3. Analysis of Granted Patents by Year
  • 8.3.4. Analysis by Geography
  • 8.3.5. Analysis by CPC Symbols
  • 8.3.6. Analysis by Type of Applicant
  • 8.3.7. Analysis by Emerging Focus Areas
  • 8.3.8. Analysis by Patent Age
  • 8.3.9. Leading Industry Players: Analysis by Number of Patents
  • 8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
  • 8.3.11. Leading Individual Assignees: Analysis by Number of Patents
• 8.4. Anti-aging Drugs: Patent Benchmarking
  • 8.4.1. Analysis by Patent Characteristics
• 8.5. Anti-aging Drugs: Patent Valuation

9. PUBLICATION ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. Anti-aging Drugs: Publication Analysis
  • 9.3.1. Analysis by Year of Publication
  • 9.3.2. Analysis by Type of Publication
  • 9.3.3. Most Popular Journals: Analysis by Number of Publications
  • 9.3.4. Most Popular Journals: Analysis by Impact Factor
  • 9.3.5. Analysis by Most Popular Keywords
  • 9.3.6. Most Popular Funding Institutes: Analysis by Number of Publications
  • 9.3.7. Most Active Publisher: Analysis by Number of Publications
  • 9.3.8. Most Popular Affiliation: Analysis by Number of Publications
  • 9.3.9. Analysis by Geography

10. PORTER'S FIVE FORCES ANALYSIS

• 10.1. Chapter Overview
• 10.2. Methodology and Key Parameters
• 10.3. Porter's Five Forces
  • 10.3.1. Threat of New Entrants
  • 10.3.2. Bargaining Power of End Users
  • 10.3.3. Bargaining Power of Drug Developers
  • 10.3.4. Threat of Substitute Products
  • 10.3.5. Rivalry Among Existing Competitors

11. COMPANY PROFILES

• 11.1. AgelessRx
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
  • 11.1.3. Recent Developments and Future Outlook
• 11.2. ANOVA Institute for Regenerative Medicine
  • 11.2.1. Company Overview
  • 11.2.2. Product Portfolio
  • 11.2.3. Recent Developments and Future Outlook
• 11.3. Betterhumans
  • 11.3.1. Company Overview
  • 11.3.2. Product Portfolio
  • 11.3.3. Recent Developments and Future Outlook
• 11.4. BioAge Labs
  • 11.4.1. Company Overview
  • 11.4.2. Product Portfolio
  • 11.4.3. Recent Developments and Future Outlook
• 11.5. bioXcellerator
  • 11.5.1. Company Overview
  • 11.5.2. Product Portfolio
  • 11.5.3. Recent Developments and Future Outlook
• 11.6. Cambrian Biopharma
  • 11.6.1. Company Overview
  • 11.6.2. Product Portfolio
  • 11.6.3. Recent Developments and Future Outlook
• 11.7. Gero.ai
  • 11.7.1. Company Overview
  • 11.7.2. Product Portfolio
  • 11.7.3. Recent Developments and Future Outlook
• 11.8. Mayo Clinic
  • 11.8.1. Company Overview
  • 11.8.2. Product Portfolio
  • 11.8.3. Recent Developments and Future Outlook
• 11.9. Rejuvenate Bio
  • 11.9.1. Company Overview
  • 11.9.2. Product Portfolio
  • 11.9.3. Recent Developments and Future Outlook
• 11.10. UT Health San Antonio
  • 11.10.1. Company Overview
  • 11.10.2. Product Portfolio
  • 11.10.3. Recent Developments and Future Outlook

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 12.1. Forecast Methodology and Key Assumptions
• 12.2. Global Anti-aging Drugs Market, 2022-2040
  • 12.2.1. Anti-aging Drugs Market: Analysis by Type of Molecule
  • 12.2.2. Anti-aging v Market: Analysis by Type of Aging
  • 12.2.3. Anti-aging Drugs Market: Analysis by Geography
    • 12.2.3.1. Anti-aging Drugs Market in North America, 2022-2040
    • 12.2.3.2. Anti-aging Drugs Market in Europe, 2022-2040
    • 12.2.3.3. Anti-aging Drugs Market in Asia Pacific, 2022-2040
    • 12.2.3.4. Anti-aging Drugs Market in Rest of the World, 2022-2040
  • 12.2.4. Anti-aging Drugs: Forecast of Individual Product Sales
    • 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues
    • 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues
    • 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues
    • 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues
    • 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues
    • 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues
    • 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues
    • 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues

13. EXECUTIVE INSIGHTS

• 13.1. Chapter Overview
• 13.2. Gero.ai
  • 13.2.1 Company Snapshot
  • 13.2.2. Interview Transcript: Co-founder and Chief Executive Officer
• 13.3. Betterhumans
  • 13.3.1. Company Snapshot
  • 13.3.2. Interview Transcript: President
• 13.4. CytoMed Therapeutics
  • 13.4.1. Company Snapshot
  • 13.4.2. Interview Transcript: Chief Operating Officer
• 13.5. Cambrian Biopharma
  • 13.5.1 Company Snapshot
  • 13.5.2. Interview Transcript: Senior Director of Global Corporate Communications
• 13.6. Landmark Medical Centre
  • 13.6.1 Company Snapshot
  • 13.6.2. Interview Transcript: Director and Consultant Obstetrician and Gynaecologist

14. APPENDIX I: TABULATED DATA

15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS